| Identification | More | [Name]
Buparvaquone | [CAS]
88426-33-9 | [Synonyms]
2-[[4-(1,1-dimethylethyl)cyclohexyl]methyl]-3-hydroxy-1,4-naphthalenedione
BUPARVAQUONE
2-((4-(1,1-dimethylethyl)cyclohexyl)methyl)-3-hydroxy-4-naphthalenedione
2-((4-tert-butylcyclohexyl)methyl)-3-hydroxy-1,4-naphthoquinone
butalex
BW-720C | [EINECS(EC#)]
618-162-1 | [Molecular Formula]
C21H26O3 | [MDL Number]
MFCD01712789 | [Molecular Weight]
326.43 | [MOL File]
88426-33-9.mol |
| Chemical Properties | Back Directory | [Appearance]
Yellow Crystalline Solid | [Melting point ]
178-184°C | [Boiling point ]
460.7±45.0 °C(Predicted) | [density ]
1.158±0.06 g/cm3(Predicted) | [storage temp. ]
Sealed in dry,2-8°C | [solubility ]
DMSO: soluble | [form ]
powder | [pka]
5.04±0.10(Predicted) | [color ]
Yellow | [Usage]
Analog of antimalarial hydroxynaphthoquinones; tert-butyl derivative of Parvaquone. Antiprotozoal (Theileria) | [Major Application]
forensics and toxicology
veterinary | [InChI]
InChI=1S/C21H26O3/c1-21(2,3)14-10-8-13(9-11-14)12-17-18(22)15-6-4-5-7-16(15)19(23)20(17)24/h4-7,13-14,24H,8-12H2,1-3H3 | [InChIKey]
KLLIVCPQDTYMLC-UHFFFAOYSA-N | [SMILES]
C1(=O)C2=C(C=CC=C2)C(=O)C(O)=C1CC1CCC(C(C)(C)C)CC1 | [CAS DataBase Reference]
88426-33-9(CAS DataBase Reference) |
| Safety Data | Back Directory | [WGK Germany ]
3 | [RTECS ]
QJ5766600 | [Storage Class]
11 - Combustible Solids | [Toxicity]
LD50 orally in rats: >2 g/kg (Hudson) |
| Hazard Information | Back Directory | [Chemical Properties]
Yellow Crystalline Solid | [Uses]
Analog of antimalarial hydroxynaphthoquinones; tert-butyl derivative of Parvaquone. Antiprotozoal (Theileria) | [Biological Activity]
Buparvaquone is a second-generation hydroxynaphthoquinone antiprotozoal drug related to parvaquone and atovaquone. Buparvaquone is indicated for the therapy and prophylaxis of all forms of Theileriosis and found to have an anti-Leishmanial activity. | [in vivo]
Treatment of N.?caninum infected mice with buparvaquone (100?mg/kg) either by intraperitoneal injection or gavage prevents neosporosis symptoms in 4 out of 6 mice in the intraperitoneally treated group, and in 6 out of 7 mice in the group receiving oral treatment[1]. Both a hydrous gel and water-in-oil emulsion of buparvaquone significantly reduce cutaneous parasite burden and lesion size, compared with the untreated control[3]. |
|
|